Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Table 3 Change from baseline in trough FEV₁ (mL) during the 1-year treatment period

Trough FEV₁ (mL), LS mean (95% CI)	Revefenacin 88 μg	Revefenacin 175 μg	Tiotropium 18 μg
Day 29	83.8 (60.4, 107.1) n = 317	124.3 (99.5, 149.1) n = 282	112.8 (89.8, 135.8) n = 330
Day 92	81.3 (57.1, 105.5) n = 287	100.0 (73.9, 126.1) n = 243	97.3 (73.7, 120.9) n = 307
Day 183	74.2 (48.6, 99.8) n = 239	104.4 (77.1, 131.7) n = 210	89.0 (64.9, 113.2) n = 283
Day 274	69.5 (43.4, 95.6) n = 223	71.4 (43.2, 99.6) n = 189	79.7 (55.0, 104.3) n = 265
Day 365	48.8 (22.3, 75.3) n = 212	52.3 (23.9, 80.6) n = 185	91.5 (66.4, 116.5) n = 248

Data are mean (standard deviation)
CI confidence interval, FEV₁ forced expiratory volume in 1 s, LS least squares

ISSN: 1465-993X